Paul Stephen Aisen is an American physician and medical researcher. He started his career as a rheumatologist and then made Alzheimer's disease his focus. As of 2015 he was on the faculty of the Keck School of Medicine of USC and his offices were in San Diego.[1]
Aisen did his undergraduate work in biochemistry and molecular biology at Harvard and obtained his medical degree from Columbia University. He did his residency at Case Western Reserve University and at Mount Sinai Medical Center in New York, and trained further through a fellowship in rheumatology at New York University. He has a private practice as a GP and rheumatologist in New York, then joined the faculty of Mount Sinai in 1994. He was recruited to the Georgetown University School of Medicine in 1999 in neurology and medicine and began focusing his practice and research on Alzheimer's disease there.[2]
In 2007 Aisen was recruited to University of California San Diego to run the Alzheimer's Disease Cooperative Study, which UCSD had established in 1991 and coordinates studies on Alzheimer's disease drugs like solanezumab.[3] He left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC's offer.[4] UCSD and USC ended up in litigation over control of the ca. $100 million program and its research data, which involved six ongoing clinical trials and data collected on thousands of clinical trial subjects.[5][6] Part of the dispute arose because Aisen's lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials.[3] USC rented space for Aisen in a San Diego office park, where Keck's Alzheimer's Therapeutic Research Institute is located under Aisen's direction.[1][7] Some aspects of data management were temporarily settled in 2016;[8] and a settlement was reached in 2019, with USC to pay UCD $50 million compensation and make a public statement that is actions "did not align with the standards of ethics and integrity which USC expects of all its faculty, administrators, and staff."[9]
Aisen has been a strong proponent of the amyloid hypothesis and as of 2017 believed that earlier intervention with drugs against amyloid might show more efficacy than interventions when the disease process is well underway, and has helped initiate large trials to test ways to prevent Alzheimer's disease.[10][11]
paul, aisen, paul, stephen, aisen, american, physician, medical, researcher, started, career, rheumatologist, then, made, alzheimer, disease, focus, 2015, faculty, keck, school, medicine, offices, were, diego, aisen, undergraduate, work, biochemistry, molecula. Paul Stephen Aisen is an American physician and medical researcher He started his career as a rheumatologist and then made Alzheimer s disease his focus As of 2015 he was on the faculty of the Keck School of Medicine of USC and his offices were in San Diego 1 Aisen did his undergraduate work in biochemistry and molecular biology at Harvard and obtained his medical degree from Columbia University He did his residency at Case Western Reserve University and at Mount Sinai Medical Center in New York and trained further through a fellowship in rheumatology at New York University He has a private practice as a GP and rheumatologist in New York then joined the faculty of Mount Sinai in 1994 He was recruited to the Georgetown University School of Medicine in 1999 in neurology and medicine and began focusing his practice and research on Alzheimer s disease there 2 In 2007 Aisen was recruited to University of California San Diego to run the Alzheimer s Disease Cooperative Study which UCSD had established in 1991 and coordinates studies on Alzheimer s disease drugs like solanezumab 3 He left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC s offer 4 UCSD and USC ended up in litigation over control of the ca 100 million program and its research data which involved six ongoing clinical trials and data collected on thousands of clinical trial subjects 5 6 Part of the dispute arose because Aisen s lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials 3 USC rented space for Aisen in a San Diego office park where Keck s Alzheimer s Therapeutic Research Institute is located under Aisen s direction 1 7 Some aspects of data management were temporarily settled in 2016 8 and a settlement was reached in 2019 with USC to pay UCD 50 million compensation and make a public statement that is actions did not align with the standards of ethics and integrity which USC expects of all its faculty administrators and staff 9 Aisen has been a strong proponent of the amyloid hypothesis and as of 2017 believed that earlier intervention with drugs against amyloid might show more efficacy than interventions when the disease process is well underway and has helped initiate large trials to test ways to prevent Alzheimer s disease 10 11 He has served as a consultant or advisor for pharmaceutical companies Eli Lilly 3 12 and Janssen 13 smaller biotech companies exploring alternative approaches to AD like Anavex Life Sciences 14 Proclara 15 CohBar 16 and Neurophage 17 as well as nonprofits like ACT AD 18 He is a principal investigator in the Alzheimer s Disease Neuroimaging Initiative 19 In November 2018 Expertscape recognized Aisen as one of the world s top ranked experts in Alzheimer s disease 20 He has an h index of 107 according to Semantic Scholar 21 References edit a b Fikes Bradley J 2 August 2015 Next steps for scientist in eye of UCSD USC Alzheimer s spat San Diego Tribune Faculty profile Paul Stephen Aisen Keck School of Medicine of USC Retrieved 15 June 2017 a b c Garde Damian August 5 2015 Judge orders a halt to Alzheimer s spat as Eli Lilly chooses sides in dispute FierceBiotech Fikes Bradley J 5 July 2015 UC San Diego sues USC and scientist alleging conspiracy to take funding data Los Angeles Times Check Hayden Erika 16 July 2015 Alzheimer s data lawsuit is sign of growing tensions Nature 523 7560 265 doi 10 1038 nature 2015 17932 Basken Paul 23 July 2015 Grant Dispute Throws an Unwritten Rule of Academic Poaching Out the Window The Chronicle of Higher Education Wang Shirley S Loftus Peter 14 October 2015 Alzheimer s Research Effort Is Ensnared in Legal Dispute Wall Street Journal Potter Matt January 11 2016 Deal gives UCSD read only rights to Alzheimer s data San Diego Reader Settlement Reached Between UCSD and USC Paul Aisen ALZForum 5 July 2019 Retrieved 21 November 2020 Elie Dolgin 16 February 2017 The new offensive on Alzheimer s disease Stop it before it starts Newsweek Sperling RA Rentz DM Johnson KA Karlawish J Donohue M Salmon DP Aisen P 19 March 2014 The A4 study stopping AD before symptoms begin Science Translational Medicine 6 228 228fs13 doi 10 1126 scitranslmed 3007941 PMC 4049292 PMID 24648338 Ornstein Charles Groeger Groeger Tigas Mike Grochowski Jones Ryann Dollars for Docs Paul Aisen ProPublica Osborne Randy January 17 2017 WashU early AD initiative could yield broader clues BioWorld Today Scientific Advisory Board Anavex Retrieved 15 June 2017 Leadership SAB Paul Aisen Proclara Biosciences Retrieved 15 June 2017 Paul Aisen M D Consultant Alzheimer s Disease CohBar Retrieved 15 June 2017 Scientific Advisory Board Neurophage Pharmaceuticals Retrieved 15 June 2017 Science Advisory Board ACT AD Retrieved 15 June 2017 Principal Investigators ADNI Retrieved 15 June 2017 Expertscape Alzheimer Disease November 2018 expertscape com November 2018 Retrieved 2018 11 15 P Aisen Semantic Scholar Retrieved 2 December 2022 Retrieved from https en wikipedia org w index php title Paul Aisen amp oldid 1192025881, wikipedia, wiki, book, books, library,
